Li You, Heavican Tayla B, Vellichirammal Neetha N, Iqbal Javeed, Guda Chittibabu
Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, NE 68198, USA.
The Sichuan Key Laboratory for Human Disease Gene Study, Clinical Laboratory Department, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072, China.
Nucleic Acids Res. 2017 Jul 27;45(13):e120. doi: 10.1093/nar/gkx315.
The RNA-Seq technology has revolutionized transcriptome characterization not only by accurately quantifying gene expression, but also by the identification of novel transcripts like chimeric fusion transcripts. The 'fusion' or 'chimeric' transcripts have improved the diagnosis and prognosis of several tumors, and have led to the development of novel therapeutic regimen. The fusion transcript detection is currently accomplished by several software packages, primarily relying on sequence alignment algorithms. The alignment of sequencing reads from fusion transcript loci in cancer genomes can be highly challenging due to the incorrect mapping induced by genomic alterations, thereby limiting the performance of alignment-based fusion transcript detection methods. Here, we developed a novel alignment-free method, ChimeRScope that accurately predicts fusion transcripts based on the gene fingerprint (as k-mers) profiles of the RNA-Seq paired-end reads. Results on published datasets and in-house cancer cell line datasets followed by experimental validations demonstrate that ChimeRScope consistently outperforms other popular methods irrespective of the read lengths and sequencing depth. More importantly, results on our in-house datasets show that ChimeRScope is a better tool that is capable of identifying novel fusion transcripts with potential oncogenic functions. ChimeRScope is accessible as a standalone software at (https://github.com/ChimeRScope/ChimeRScope/wiki) or via the Galaxy web-interface at (https://galaxy.unmc.edu/).
RNA测序技术不仅通过精确量化基因表达,还通过鉴定嵌合融合转录本等新型转录本,彻底改变了转录组特征分析。“融合”或“嵌合”转录本改善了多种肿瘤的诊断和预后,并推动了新型治疗方案的发展。目前,融合转录本检测是通过几个软件包来完成的,主要依靠序列比对算法。由于基因组改变导致的错误比对,癌症基因组中融合转录本位点的测序读数比对极具挑战性,从而限制了基于比对的融合转录本检测方法的性能。在此,我们开发了一种全新的无比对方法ChimeRScope,它基于RNA测序双端读数的基因指纹(作为k-mer)图谱准确预测融合转录本。在已发表数据集和内部癌细胞系数据集上的结果以及随后的实验验证表明,无论读数长度和测序深度如何,ChimeRScope始终优于其他常用方法。更重要的是,我们内部数据集的结果表明,ChimeRScope是一个更出色的工具,能够识别具有潜在致癌功能的新型融合转录本。可通过(https://github.com/ChimeRScope/ChimeRScope/wiki)获取独立软件形式的ChimeRScope,或通过(https://galaxy.unmc.edu/)的Galaxy网络界面获取。